6139 ASE Engineering and Construction Co., Ltd. Announces Cumulative Disposal of Marketable Securities Exceeding NTD 300 Million

Announcement Date: May 16, 2026 Spokesperson Date: May 15, 2026 Spokesperson Time: 16:36:59 Company Code: 6139 Company Name: ASE Engineering and Construction Co., Ltd. Subject: Announcement of the company's cumulative disposal of the same marketable securities exceeding NTD 300 million. Applicable Clause: Article 20 Date of Occurrence of the Event: May 15, 2026 Description: 1. Name of securities: Common stock of PharmaEssentia Corp. 2. Transaction date: 2025/5/28 to 2026/5/15. 3. Date of Board Resolution: Not applicable. 4. Other Approval Dates: Approval Level: Handled in accordance with company's approval authority May 15, 2026 5. Transaction quantity, unit price, and total transaction amount: Transaction quantity: 467,000 shares Unit price: Average NTD 688.76 per share Total transaction amount: NTD 321,651,000 6. Disposal gain (or loss) (not applicable to acquisition of marketable securities): Disposal gain NTD 282,498,115 7. Relationship with the target company of the transaction: None 8. As of now, the quantity, amount, shareholding ratio, and restrictions on rights (e.g., pledge status) of cumulative holdings of these securities (including this transaction): Remaining holdings: 158,330 shares; Amount: NTD 12,270,003; Shareholding ratio: 0.04%; Restrictions on rights: None 9. As of now, the proportion of investment in marketable securities (including this transaction) listed in Article 3 of the "Regulations Governing the Acquisition or Disposal of Assets by Public Companies" to the company's total assets and owners' equity attributable to the parent company in the latest financial report, and the working capital amount in the latest financial report: Proportion of total assets: 31.82%; Proportion of owners' equity attributable to the parent company: 78.91%; Working capital amount: NTD 5,711,366,634 10. Specific purpose of acquisition or disposal: To enrich operating capital and increase revenue. 11. Opinions of directors who dissented from this transaction: None 12. Is this transaction a related party transaction: No 13. Counterparty of the transaction and its relationship with the company: None 14. Date of approval by supervisors or audit committee: Not applicable 15. Date of previous significant announcement on the same event: Not applicable 16. Other matters to be specified: PharmaEssentia Corp. issued new shares of 43,935 shares in October 2025.